Press Release

Kiadis Pharma to present at the American Society of Hematology 2019 Annual Meeting

November 6, 2019 at 11:00 AM EST

ASH Abstract #

ATIR101: 592, 4464; NK-cell Therapy (K-NK002) 1955

  • Phase II data analysis of ATIR101 as an adjunctive treatment following T-cell depleted haploidentical hematopoietic stem cell transplantation
  • Trial-in-progress overviews of Phase III ATIR101 and Phase II NK-cell Therapy (K-NK002) clinical trial programs

Amsterdam, The Netherlands, November 6, 2019 – Kiadis Pharma N.V. (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces abstracts showcasing the potential of the company’s pipeline therapies, (ATIR101 and K-NK002), will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place December 7–10 in Orlando, Florida.

New ATIR101 data will be discussed in an oral presentation exploring the effect of a single infusion of ATIR101 on survival outcomes in patients with blood cancer (including acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], and myelodysplastic syndromes [MDS]) who underwent T-cell depleted haploidentical-hematopoietic stem cell transplantation (haplo-HSCT) from a pooled analysis of two Phase II trials (CR-AIR-007, NCT01794299; CR-AIR-008, NCT02500550). Additionally, a trial-in-progress (TIP) overview of the global, randomized ATIR101 Phase III trial (NCT02999854) will be presented, describing the head-to-head comparison of outcomes of patients who receive ATIR101 after T-cell depleted haplo-HSCT compared to the commonly applied approach of using post-transplant chemotherapy with cyclophosphamide (PTCy) in patients who have received a T-cell replete haplo-HSCT.

Kiadis Pharma will also provide a TIP overview of the multi-center Phase II trial (BMT CTN 1803) evaluating the efficacy of K-NK002, Kiadis Pharma’s recently acquired adjunctive immunotherapeutic, in decreasing risk of relapse in patients with high-risk AML or MDS undergoing haplo-HSCT.

“Our presence at ASH demonstrates our long-term commitment to developing personalized, next-generation cell therapies for some of the hardest to treat blood cancers,” said Arthur Lahr, CEO of Kiadis Pharma. “By applying highly innovative science in our clinical programs, we believe our pipeline has potential to bring us closer to addressing critical unmet needs, not just for patients, but for the healthcare professionals that treat them.”

Kiadis Contacts:

Kiadis Pharma:
Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305
m.cimino@kiadis.com

Kiadis Pharma Company Abstracts at ASH 2019

Medicine Abstract Number Lead Author Abstract Title Presentation Type Presentation time
ATIR101

 
592 Denis Claude Roy Addition of ATIR101, an Adjunctive Treatment following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

 
Oral Session Name: 711. Cell Collection and Processing
Session Date: Monday, December 9, 2019
Session Time: 7:00 AM - 8:30 AM
Presentation Time: 7:45 AM
Room: Orange County Convention Center, W414AB

 
4464 Denis Claude Roy Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III HATCY Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide Poster Session Name: 704. Immunotherapies: Poster III
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM
Location: Orange County Convention Center, Hall B

 
K-NK002 (Previously CSTD002) 1955 Sumithira Vasu BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-transplant Relapse in AML and MDS (NK-REALM)

 
Poster Session Name: 704. Immunotherapies: Poster I 
Date: Saturday, December 7, 2019 
Presentation Time: 5:30 PM - 7:30 PM 
Location: Orange County Convention Center, Hall B

About ATIR101 and K-NK002
Administered as adjunctive immunotherapeutics on top of HSCT, ATIR101 and K-NK002 provide lymphocyte infusions with functional, mature and potent immune cells from a haploidentical family member. The T-cells in ATIR101 and NK-cells in K-NK002 will help fight infections and remaining tumor cells, until the immune system has fully re-grown from stem cells in the transplanted graft. In addition, K-NK002 has shown promise in the treatment of relapse/refractory AML.

In ATIR101, T-cells that would cause GVHD are depleted from the donor lymphocytes, using our photodepletion technology. At the same time, ATIR101 contains potential cancer-killing T-cells from the donor that could eliminate residual cancer cells and help prevent relapse of the disease. Furthermore, the donor lymphocytes retain their immune function and help protect the patient from infection.

In K-NK002, nanoparticle processing technology enables improved ex vivo expansion and activation of NK-cells supporting multiple high-dose infusions with potent anti-cancer cytotoxicity.

About Kiadis
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY KIADIS PHARMA N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons
Viewing the materials contained herein may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

In particular, unless otherwise determined by Kiadis Pharma N.V. and permitted by applicable law and regulation, it is not intended that any offering by Kiadis Pharma N.V. of the securities mentioned in such materials (the "Securities") would be made, or any documentation be sent, directly or indirectly, in or into Australia, Canada, Japan, South Africa or the United States.

The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for the Securities in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The offer and sale of the Securities has not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. No public offering of the Securities is being made in the United States.

The Securities will not be registered under or offered in compliance with applicable securities laws of any state, province, territory, county or jurisdiction of Australia, Canada, Japan or South Africa. Accordingly, unless an exemption under the relevant securities law is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly, in or into Australia, Canada, Japan, South Africa or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access
Access to these materials is being made available on this webpage by Kiadis Pharma N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Kiadis Pharma N.V. that they are doing so for information purposes only.

None of the materials made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, securities in Kiadis Pharma N.V. and cannot be relied upon for any investment contract or decision. Further, such materials do not constitute a recommendation by Kiadis Pharma N.V. or any other party to sell or buy securities in Kiadis Pharma N.V.

Unless otherwise determined by Kiadis Pharma N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into Australia, Canada, Japan, South Africa, the United States or any other jurisdictions where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into or from Australia, Canada, Japan, South Africa, the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer
I certify that I am not located or resident in, nor is the partnership or corporation on whose behalf I am accessing the website organised or incorporated under the laws of, Australia, Canada, Japan, South Africa or the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I will not transmit or otherwise send any materials contained in this website to any person located or resident in (or organised or incorporated under the laws of) Australia, Canada, Japan, South Africa or the United States.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.

Agree Disagree